April 2026 Research Update

This month added two different kinds of treatment evidence for wild-type ATTR cardiomyopathy: one large real-world analysis of tafamidis and one very small early trial of a new approach using low-dose radiotherapy. Together, these studies support that tafamidis treatment was linked with lower death rates in routine care, while radiotherapy is still at the stage of testing safety and looking for early signals on scans. A practical point that became clearer is that who receives treatment can vary by patient group, even within wild-type disease.

In a large international cohort of 1,454 people with wild-type ATTR cardiomyopathy, tafamidis use was associated with lower all-cause mortality in the overall analysis and in a matched treated-versus-untreated comparison (reported HR 0.44). The study also reported that tafamidis was started less often in women, even though the observed treatment effect did not show a clear difference by sex in this dataset. The same report noted that disease stage at the time of treatment (NAC stage) related to mortality while on tafamidis, highlighting that outcomes differed by how advanced the condition was when treatment began. [1]

In an exploratory first-in-human trial of 5 people with wild-type ATTR cardiac amyloidosis, low-dose radiotherapy to the left ventricle was reported as well tolerated over 6 months, with no grade 3 or higher treatment-related adverse events. Amyloid PET scan uptake tended to decrease in most participants, but heart MRI measures like native T1 and left ventricular mass did not improve, and short-term clinical and functional changes varied between people. This keeps radiotherapy in the "early research" category: it shows feasibility and safety signals, but it is too small to say what it does for symptoms or long-term outcomes. [2]

For patients and caregivers, the strongest information this month is about tafamidis in routine care: in a large cohort it was linked with lower mortality, and the study did not find clear evidence that women benefit less than men. At the same time, the report raises an access and equity question, because fewer women in this dataset started tafamidis. The radiotherapy study mainly matters as early research, because it focused on tolerability and scan changes in only 5 people, and it did not show clear improvements on other heart imaging measures within 6 months. [1]

What remains uncertain is how much the PET scan changes seen after radiotherapy translate into how people feel or function, and whether any effects last beyond the short follow-up. For tafamidis, this was not a randomized trial, so the study can compare outcomes in treated and untreated groups but cannot remove all differences between them. Even with those limits, these studies add a clearer picture of what is being explored next (radiotherapy) and where real-world care patterns may leave some people less likely to receive established therapy. [2]

Several studies this month focused on finding heart involvement earlier, or with tests that could be easier to access than today’s standard pathways. Across these studies, newer imaging and computer-based tools often separated people with amyloid heart disease from controls, and one PET method detected heart uptake even when other scans were negative. At the same time, work using diagnosis codes showed that performance can drop when tools are moved across health systems, reminding readers that "works in one place" does not always mean "works everywhere."

A small study using cardiac time-harmonic elastography (an ultrasound-based stiffness mapping approach) reported near-perfect separation between 11 people with wild-type ATTR and 10 healthy controls (AUC about 1.00). In plain terms, the method aims to measure how stiff the heart muscle is during relaxation, which is a key problem in amyloid cardiomyopathy. The authors also checked the approach against computer simulations and reported close agreement, with underestimation only in a rare heart-wall configuration. [3]

In another small imaging study (10 people with rare amyloidosis and 12 controls), 124I-evuzamitide PET/CT showed visible heart uptake in all participants who already had cardiomyopathy, while controls had no uptake. Notably, 3 of 4 participants without known cardiomyopathy still showed heart uptake even though other heart imaging tests were negative, and a quantitative uptake measure separated the groups. This raises the possibility that this PET approach could detect heart involvement earlier than some existing tests, but the numbers were small and the amyloidosis types were mixed. [4]

Two studies tested computer-based detection using information that is already collected in many clinics, but they showed different kinds of challenges. An ECG-based AI model tested in 2,901 adults reported good overall performance for identifying ATTR cardiomyopathy (AUC 0.88), with similar accuracy in wild-type and hereditary ATTR and somewhat lower sensitivity in very early presentations (like asymptomatic disease). In contrast, a diagnosis-code-based model transferred from the US to a German setting could still identify ATTR-CM cases but had lower sensitivity and specificity than prior validations and could not separate wild-type from hereditary ATTR-CM, with performance strongly affected by how detailed the coding was. [5] [6]

A large Japanese cohort of 1,506 people with ATTR cardiomyopathy described how diagnosis is being made in real practice, showing frequent use of noninvasive nuclear imaging (99mTc scans with SPECT) along with blood testing, and a substantial proportion still having heart biopsy. Many people were recorded as having milder heart-failure symptoms (NYHA I-II), which fits with the idea that diagnosis is happening earlier for some patients. This study does not test a new tool, but it helps explain the current diagnostic landscape that new tools would need to fit into. [7]

For patients, these studies mainly add to the direction of travel: researchers are trying to detect ATTR cardiomyopathy earlier and with tests that could be less invasive or more widely available, such as advanced ultrasound, PET scanning, and automated reading of standard ECGs. Right now, most of this remains research because several results came from small groups, and performance in one hospital system may not match another. The large Japan registry paper matters now in a different way: it describes what diagnostic testing people actually receive in clinical practice, including how often noninvasive scans and biopsy are used. [3] [7]

What remains uncertain is whether imaging signals that look "earlier" (like PET uptake when other scans are negative) predict future symptoms, progression, or response to treatment. It is also not yet clear how ECG-AI tools should be used alongside existing workups, especially for very early disease where sensitivity was lower, or across countries where coding and data capture differ. Even so, these studies make it clearer why research is pushing toward simpler screening and why careful validation in different settings is essential before tools can be relied on broadly. [4] [5] [6]

This month’s observational studies reinforced that ATTR amyloidosis affects daily life mostly through physical limits, and that heart rhythm problems and nerve problems are common alongside the heart disease. Across large and small patient groups, physical functioning and energy were reduced, while mental health scores often stayed closer to population norms. Other studies added detail on specific contributors, including atrial fibrillation, small-vessel heart blood flow problems, and peripheral neuropathy.

In a large quality-of-life analysis from a specialized center (836 people with ATTR amyloidosis), physical health scores were substantially lower than population norms across ATTR groups, while mental health scores were near average. The most affected areas included limits in usual roles due to physical health and lower vitality, which many people would experience as fatigue and reduced ability to keep up with normal activities. The pattern was similar across ATTR types, with the V122I hereditary group having the lowest physical scores in this dataset. [8]

Heart rhythm and circulation studies highlighted common heart-related complications in wild-type ATTR cardiomyopathy, without implying that everyone will experience them. In a cohort of 108 people with cardiac amyloidosis, atrial fibrillation was frequent and was reported much more often in wild-type ATTR cardiac amyloidosis (80%) than in AL amyloidosis (33%), and it tended to occur in older people and those with more severe heart disease features. In a separate prospective study comparing 32 people with wild-type ATTR cardiomyopathy to 32 with other causes of thickened heart muscle, coronary microvascular dysfunction was common in both groups, but only in the wild-type ATTR group did the microvascular measurements relate to troponin T, a blood marker linked with heart muscle injury. [9] [10]

A small study focusing on nerves in 14 older men with wild-type ATTR reported that signs of peripheral neuropathy were very common on exam (92.9%) and also present on nerve testing in many (71.4%), usually affecting both sensation and movement. Measures related to sweat gland nerve function were often abnormal, while symptom questionnaires suggested a more limited impact on autonomic symptoms in this group. Many participants also reported reduced quality of life on a neuropathy-focused questionnaire, linking nerve involvement to everyday impact. [11]

For patients and caregivers, these studies help put common experiences into words: physical limitations and low energy are a consistent part of living with ATTR, even when mental well-being can remain relatively stable on average. They also clarify that wild-type ATTR cardiomyopathy is often accompanied by other issues, such as atrial fibrillation and, in some groups, nerve involvement that may affect sensation, strength, or daily function. This information mostly adds understanding and context rather than changing treatment decisions, because these studies describe patterns rather than testing an intervention. [8] [11]

What remains uncertain is how these findings vary across different clinics and patient groups, since some studies were from specialized centers and one neuropathy study included only 14 men. The microvascular dysfunction study also shows that some findings are not unique to amyloid, because similar rates were seen in a comparison group with thickened hearts, even though the link to troponin T appeared specific to the wild-type ATTR group. Still, taken together, these studies make it clearer which symptoms and related conditions are commonly measured in research and why quality of life is an important outcome alongside scans and lab tests. [10] [9]

The case reports this month broadened the picture of where transthyretin amyloid can show up, including outside the heart. One report in wild-type ATTR described amyloid deposits in spinal tissues linked with spinal stenosis symptoms, while another report (not wild-type) examined amyloid fibril structure in different organs. Together, these reports do not change what is known for most patients, but they add concrete examples that ATTR amyloid can vary by location and physical form.

A case report of a 72-year-old woman with wild-type ATTR described amyloid deposits in thickened spinal ligaments in both the neck and lower back, and also in a bulging lumbar intervertebral disc. The authors noted that amyloid in the disc is rare in wild-type ATTR and raised the possibility of a link with disc degeneration. For readers, the main point is that ATTR amyloid can sometimes be found in spinal tissues, including the ligaments and, rarely, an intervertebral disc; whether these deposits contribute to disc degeneration remains uncertain. [12]

Another single-patient report used high-resolution lab imaging (cryo-electron microscopy) to look at transthyretin amyloid fibrils from the heart and liver in a person with a hereditary ATTR variant (V122 deletion) and polyneuropathy. The fibrils had more than one structural form, appearing as both single and double filaments. This is basic-science-style evidence in one person, but it supports the idea that differences in amyloid structure could help explain why ATTR can look different from person to person and organ to organ. [13]

For patients with wild-type ATTR, the spine case report matters mainly as awareness that amyloid deposits can sometimes be found in tissues involved in spinal stenosis, not only in the heart. This does not mean that everyone with wild-type ATTR will develop spinal problems, but it adds an example that helps connect ATTR with some "red-flag" orthopedic issues that can appear earlier. The cryo-EM case is mainly research and does not translate directly into care, but it contributes to long-term efforts to understand why symptoms and organ involvement vary. [12] [13]

What remains uncertain is how often disc or ligament deposits occur in wild-type ATTR and how strongly they contribute to symptoms compared with age-related spine changes, because this was a single case. It is also unknown how common the different fibril structures are across larger groups or whether they predict progression, since the structural study included only one person and was not in wild-type disease. Even with those limits, these reports expand the mental picture of ATTR as a condition that can affect multiple tissues and can have biologic variation at the microscopic level. [12] [13]